Illumina, Inc.: stock overview

ILMNNASDAQHealthcare · Laboratory Analytical Instruments

Price

$207.01

November 13, 2026Market cap $31.7B

What Ploutos Investor adds for Illumina

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 17 fiscal years, from FY2009
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

In short

Illumina had revenue of $4.5B over the last 12 months and net income of $895M, a net margin of 19.7%. Revenue grew by 6.0% a year on average over the last 5 years. At $207.01 the shares trade at a P/E of 35.4. It has net debt of $452M. It pays no dividend.

From its SEC filings (latest fiscal year to December 28, 2025) and the price of November 13, 2026.

Its SEC filings
Market cap
$31.7B
153M shares
P/E
35.4
Revenue, 12 months
$4.5B
+6.0% a year over 5 years
Net margin
19.7%
FY2025: 19.6%, above 90% of its industry

Worth knowing

What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.

3 fiscal years in figures

Each fiscal year's figures as the company filed them, and the share price at its end.

2023–FY2025 fiscal years

-1.8% a year over 2 years

  • FY2025Dec 28, 202510-K
    Revenue$4.3B
  • FY2024Dec 29, 202410-K
    Revenue$4.4B
  • 202310-K
    Revenue$4.5B

Fiscal years in figures

ILMN's revenue, profit, cash flow and dividend with each year-end price, from FY2009 to FY2022, 14 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Key figures

The company's current figures in five groups. Each term is explained behind its ⓘ.

Valuation

Market cap 3-year median: $21.4B
$31.7B
Enterprise value 
$32.1B
P/E 
35.4
EV / EBIT 
33.4
EV / Revenue 
7.1
P/B 3-year median: 7.6
10.1
FCF yield 3-year median: 3.3%
3.3%
Earnings yield 3-year median: -5.3%
2.8%

Profitability

Gross margin 
67.9%
Operating margin 
21.2%
Net margin 3-year median: -25.8%
19.7%
ROIC 
17.3%
ROIC, 5-year average 
-10.5%
ROE 
32.5%

Growth

Revenue, yearly change 
-0.7%
EPS, yearly change 
–
FCF, yearly change 
+31.3%
Revenue, average a year 
+6.0%
EPS, average a year 
+4.1%

The yearly change compares FY2025 with FY2024.

Balance sheet

Cash 
$1.3B
Total debt 
$2.3B
Of which operating leases 
$524M
Net debt 
$452M
Net debt / EBITDA 
0.4x
Interest cover 
9.8x
Current ratio 
2.63

Balance sheet of September 27, 2026.

Returns to shareholders

Dividend yield 
0.00%
Buybacks 
2.34%
Total returned 
2.34%
Shares, yearly change 
-3.5%
Valuation against its own pastEach fiscal year's P/E, P/FCF and P/B beside today's, and the DCF calculator for the company.Valuation

Against its industry

Where its margins and returns stood in fiscal 2025 among the SEC filers of its industry (SIC code 38).

Gross margin

66.1%

Above 70% of the 161 companies in its industry, and 83% of all.

Operating margin

18.6%

Above 84% of the 186 companies in its industry, and 81% of all.

Net margin

19.6%

Above 90% of the 189 companies in its industry, and 81% of all.

ROE

31.2%

Above 96% of the 174 companies in its industry, and 92% of all.

ROA

12.8%

Above 89% of the 190 companies in its industry, and 92% of all.

Revenue growth

-0.7%

Above 20% of the 186 companies in its industry, and 26% of all.

From the yearly figures every company files with the SEC, for those with revenue of at least $25 million. The industry is the first two digits of the SIC code.

The company at the SEC

How it is registered and when its fiscal year ends.

Name at the SEC
ILLUMINA, INC.
Exchange
NASDAQ
Industry (SIC)
3826 · Laboratory Analytical Instruments
Fiscal year ends
January 3
Latest annual report
December 28, 2025
Reporting currency
USD
Shares
153M

Other companies: Healthcare

The largest companies of the same sector, each with its own page.

The Healthcare sectorAll companies

The full analysis

What do Illumina's filings show?

These are Illumina's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about ILMN

Didn't find what you were looking for?

Ask us
What is ILMN's market cap?

Illumina, Inc.'s market cap is $31.7B, at a price of $207.01 on November 13, 2026 and 153M shares.

What is ILMN's P/E?

ILMN's P/E is 35.4, on earnings per share of $5.81 over the last 12 months.

How much revenue does ILMN have?

Illumina had revenue of $4.5B over the last 12 months. Over the last 5 years it changed by +6.0% a year on average.

Does ILMN pay a dividend?

No. Illumina paid no regular dividend over the last 12 months.

Where do the figures come from?

From Illumina, Inc.'s SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.